Related Experiment Videos

Human beta cells are exceedingly resistant to streptozotocin in vivo

Hua Yang1, James R Wright

  • 1Department of Pathology, Izaak Walton Killam Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.

Endocrinology
|June 20, 2002
PubMed

Insights

Human beta cells show remarkable resistance to streptozotocin (STZ), a diabetes-inducing agent. This study found human islets transplanted into mice were protected from STZ toxicity, unlike rodent or fish islets.

Area of Science:

  • Endocrinology
  • Diabetes Research
  • Cell Biology

Background:

  • Streptozotocin (STZ) induces beta cell death in rodents through DNA damage and nicotinamide adenine dinucleotide depletion.
  • The susceptibility of human beta cells to STZ remains incompletely understood.

Purpose of the Study:

  • To investigate the resistance of human beta cells to streptozotocin (STZ) compared to rodent and fish islets.
  • To determine if the STZ-induced beta cell death mechanism observed in rodents is applicable to human beta cells.

Main Methods:

  • Islets from mice, rats, tilapia, and humans were transplanted into diabetic nude mice.
  • Recipients were injected with increasing doses of STZ, and plasma glucose levels were monitored.
  • Glucose tolerance tests and islet histology were performed to assess beta cell function and survival.

Main Results:

  • Human islet recipients showed resistance to STZ doses up to 450 mg/kg.
  • Rodent islet recipients exhibited dose-dependent diabetes induction.
  • Fish (tilapia) islet recipients demonstrated significant resistance to STZ.

Conclusions:

  • Human beta cells are exceedingly resistant to streptozotocin (STZ).
  • The mechanism of STZ-induced beta cell death in rodents does not appear to directly translate to human beta cells.
  • These findings have implications for understanding diabetes pathogenesis and therapeutic strategies.

Related Concept Videos